Coreg Cr Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40000 WAYLIS THERAP Method of treatment for decreasing mortality resulting from congestive heart failure
Jun, 2015

(9 years ago)

US6022562 WAYLIS THERAP Medicinal and/or nutritional microcapsules for oral administration
Oct, 2015

(8 years ago)

USRE40000

(Pediatric)

WAYLIS THERAP Method of treatment for decreasing mortality resulting from congestive heart failure
Dec, 2015

(8 years ago)

US6022562

(Pediatric)

WAYLIS THERAP Medicinal and/or nutritional microcapsules for oral administration
Apr, 2016

(8 years ago)

US7268156 WAYLIS THERAP Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Jun, 2023

(1 year, 18 days ago)

US7268156

(Pediatric)

WAYLIS THERAP Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Dec, 2023

(6 months ago)

US8101209 WAYLIS THERAP Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(1 year, 1 month from now)

US8101209

(Pediatric)

WAYLIS THERAP Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Mar, 2026

(1 year, 7 months from now)



Coreg Cr is a drug owned by Waylis Therapeutics Llc. It is used for managing congestive heart failure and hypertension to reduce mortality. Coreg Cr uses Carvedilol Phosphate as an active ingredient. Coreg Cr was launched by Waylis Therap in 2006. It is is available in capsule, extended release form for oral use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 11, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Decreasing mortality caused by congestive heart failure; Treatment of congestive heart failure

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents